Dr Nan Chen speaks to ecancer about the Impact of anthracyclines in high genomic risk node-negative HR+/HER2- breast cancer.

The study evaluates the effectiveness of anthracyclines (T-AC) in treating HR-positive and HER2-negative breast cancer.

It compares taxane and anthracycline/cyclophosphamide and similar regimens to taxane plus cyclophosphamide (TC) chemotherapy, focusing on recurrence scores and survival outcomes.

Higher recurrence scores are linked to better five-year survival rates for patients on anthracyclines, especially in tumours two centimetres or larger.

The analysis suggests using recurrence scores as a biomarker for treatment decisions while considering risks like cardiotoxicity.